主页 > 医学动态 >
【drug-news】复方乐卡地平依那普利即将于意大利
RECORDATI signs co-marketing agreement with SIGMA-TAU in Italy
for its new antihypertension product
MILAN, ITALY -- (MARKET WIRE) -- December 21, 2006 -- Recordati announced that it has signed a non-exclusive agreement with sigma-tau, a leading Italian pharmaceutical company, for the marketing and sale in Italy of its new antihypertensive drug which combines lercanidipine and enalapril. The launch is expected to take place at the beginning of 2008 following approval in 2007. The new specialty, a fixed combination of lercanidipine and enalapril, was approved in Germany as announced on 27 July last. Germany will act as Reference Member State in the mutual recognition process for the rest of Europe which is expected to be completed during 2007.
Agreements have already been finalized with other partners in France, Spain, Benelux, the Nordic countries including Finland, Korea, Australia, Taiwan, the Middle East including Israel, and South Africa. Further agreements are near completion.
Most hypertensive patients, especially those with other associated risk factors, now require multiple therapies using more than one drug to keep their blood pressure at desired levels. Fixed combinations of more than one antihypertensive agent will therefore play a significant and increasing role in the future hypertension market. The advantages of fixed combinations as opposed to the administration of separate treatments are significant. The combined dosages of the drugs are those broadly used by the physician and their efficacy and tolerability have been proven in clinical trials. The reduction of the number of pills a patient must take, especially in the elderly, increases patient compliance - which is extremely important in chronic treatments aimed at reducing and preventing cardiovascular risk.
"We are delighted to have sigma-tau as co-marketer in Italy for our new drug", stated Giovanni Recordati, Chairman and CEO. "I am confident that sigma-tau, one of the leading pharmaceutical companies in Italy, will contribute effectively to extend the use of this new therapeutic option for the treatment of hypertension."
译文
MILAN, ITALY -- (MARKET WIRE) -- December 21, 2006 -- Recordati announced that it has signed a non-exclusive agreement with sigma-tau, a leading Italian pharmaceutical company, for the marketing and sale in Italy of its new antihypertensive drug which combines lercanidipine and enalapril. The launch is expected to take place at the beginning of 2008 following approval in 2007. The new specialty, a fixed combination of lercanidipine and enalapril, was approved in Germany as announced on 27 July last. Germany will act as Reference Member State in the mutual recognition process for the rest of Europe which is expected to be completed during 2007.
米兰.意大利（市场快报）2006.12.21 意大利Recordati公司宣布与意大利首席制药公司sigma-tau就其新药复方乐卡地平依那普利的市场开拓与下手达成一项非独家协议。在2007年获得审批后，预计于2008年正式启动。复方乐卡地平依那普利已经于2006年7月27日获得德国批准，该国在欧洲相互承认程序中扮演了参照国的角色，因而欧洲其余国家有望在2007年通过对该药品的审批。
Agreements have already been finalized with other partners in France, Spain, Benelux, the Nordic countries including Finland, Korea, Australia, Taiwan, the Middle East including Israel, and South Africa. Further agreements are near completion.
该协议确定的其他伙伴来自如下国家：法国、西班牙、比利时-荷兰-卢森堡经济联盟、包括芬兰的北欧国家、韩国、澳大利亚、台湾、包括以色列的中东地区以及南非。进一步的协议几近完成。
Most hypertensive patients, especially those with other associated risk factors, now require multiple therapies using more than one drug to keep their blood pressure at desired levels. Fixed combinations of more than one antihypertensive agent will therefore play a significant and increasing role in the future hypertension market. The advantages of fixed combinations as opposed to the administration of separate treatments are significant. The combined dosages of the drugs are those broadly used by the physician and their efficacy and tolerability have been proven in clinical trials. The reduction of the number of pills a patient must take, especially in the elderly, increases patient compliance - which is extremely important in chronic treatments aimed at reducing and preventing cardiovascular risk.
大多数高血压患者，尤其是伴有危险因素的高血压患者，需要使用多种药物，进行多重治疗以便将控制血压在理想水平。多种抗高血压药物的固定联合应用将在以后的高血压时市场扮演越来越重要的角色。与分别应用相比，联合应用的优点是显著的。药物联合应用的剂量是临床医师广泛应用的，其有效性与耐受性已被诸多的临床试验所证明。患者，尤其是老年患者必用药物数量的减少可增加患者的依从性，而这对于以降低和预防心血管风险为目的的长期治疗来说是至关重要的。
阅读本文的人还阅读：
作者:admin@医学,生命科学 2011-02-17 05:14
医学,生命科学网